{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:59:28Z","timestamp":1791266368221,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,15]]},"DOI":"10.1093\/cid\/cis391","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T16:43:04Z","timestamp":1340124184000},"page":"S16-S24","source":"Crossref","is-referenced-by-count":23,"title":["Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis\u00a0C"],"prefix":"10.1093","volume":"55","author":[{"given":"Alyson N.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,7,15]]},"reference":[{"key":"key\n\t\t\t\t20171014010609_CIS391C1","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical practice. Chronic hepatitis C infection","volume":"364","author":"Rosen","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20171014010609_CIS391C6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-150-8-200904210-00007","article-title":"Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial","volume":"150","author":"Jensen","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C8","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1572-0241.2005.00282.x","article-title":"A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C","volume":"100","author":"Jacobson","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171014010609_CIS391C9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C10","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20171014010609_CIS391C11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/JVI.00328-07","article-title":"Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein","volume":"82","author":"Tellinghuisen","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20171014010609_CIS391C12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","article-title":"Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide","volume":"87","author":"Kim","year":"1996","journal-title":"Cell"},{"key":"key\n\t\t\t\t20171014010609_CIS391C13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C17","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 PI, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014010609_CIS391C19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014010609_CIS391C21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J Clin Virol"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C22","first-page":"1429A","article-title":"MC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study","volume":"54","author":"Fried","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C23","first-page":"473A","article-title":"Treatment with the 2nd generation HCV PI BI 201335 results in high and consistent SVR rates\u2013results from SILEN-C1 in treatment-na\u00efve patients across different baseline factors","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C24","first-page":"398A","article-title":"High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40KD) and ribavirin (P\/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study","volume":"54","author":"Terrault","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C25","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/S0168-8278(11)61378-0","article-title":"The ASPIRE trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN\/RBV treatment: week 24 interim analysis","volume":"54","author":"Zeuzem","year":"2011","journal-title":"J Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C26","first-page":"992A","article-title":"High rapid virologic response (RVR) with ACH-1625 daily dosing plus pegifnalpha 2a\/RBV in a 28-day phase 2a trial","volume":"54","author":"Lalezari","year":"2011","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The PI GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C28","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"HCV cured without peginterferon\/ribavirin with 2 oral HCV drugs BMS790052\u00a0+\u00a0BMS650032: quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders: HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052\u00a0+\u00a0BMS650032","volume":"52","author":"Lok","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C29","first-page":"543A","article-title":"MK-5172, a second generation HCV NS3\/4A PI is active against common resistance associated variants (RAVs) and exhibits cross-genotype activity","volume":"54","author":"Graham","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C30","first-page":"427A","article-title":"Once-daily PSI-7977 Puls Peg\/RBV in treatment naive patients with HCV GT1: robust end of treatment response rates are sustained post- treatment","volume":"54","author":"Lawitz","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl)","key":"key\n\t\t\t\t20171014010609_CIS391C31","first-page":"1435A","article-title":"Interim data from phase 2 study showed 93% of people with hepatitis C who received a total of 12 weeks of a combination regimen including INCIVEK\u2122 (telaprevir) and VX-222 (400mg) achieved a viral cure (SVR)","volume":"54","author":"Nelson","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C32","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S0168-8278(11)60427-3","article-title":"Four-week treatment with GS-9256 and tegobuvir (GS-9190),\u00a0\u00b1\u00a0RBV\u00a0\u00b1\u00a0PEG, results in enhanced viral suppression on follow-up PEG\/RBV therapy, in genotype 1A\/1B HCV patients","volume":"52","author":"Foster","year":"2011","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171014010609_CIS391C33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C34","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the PI boceprevir in hepatitis C virus\u2013infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014010609_CIS391C35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014010609_CIS391C36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C37","first-page":"1428A","article-title":"Dual oral combination therapy with the NS5A inhibitor daclatasvir (DCV; BMS-790052) and the NS3 PI asunaprevir (ASV; BMS-650032) achieved 90% sustained virologic response (SVR12) in Japanese HCV genotype 1b\u2013infected null responders","volume":"54","author":"Chayama","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C38","first-page":"1436A","article-title":"Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C39","first-page":"377A","article-title":"Once daily PSI-7977 pus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment naive patients with HCV GT2 or GT3","volume":"54","author":"Gane","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014010609_CIS391C40","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(11)61156-2","article-title":"Once daily alisporivir (DEB025) plus peg-IFN-alfa-2A\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naive patients\u2014 the ESSENTIAL study","volume":"52","author":"Flisiak","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl)","key":"key\n\t\t\t\t20171014010609_CIS391C41","first-page":"1430A","article-title":"A randomized, double-blind, placebo controlled safety and anti-viral proof of concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 chronic HCV infection","volume":"54","author":"Janssen","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C42","first-page":"S560","article-title":"High sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results","volume":"56","author":"Sulkowski","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C43","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(12)61218-5","article-title":"ABT-072 or ABT-333 combined with pegylated interferon\/rivabirin after 3-day monotherapy in HCV genoptype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C44","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(12)60027-0","article-title":"A 12-week interferon-free regimen of ABT-450\/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype-1-infected subjects","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C45","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","article-title":"Electron: once daily PSI-7977 plus RBV in HCV GT1\/2\/3","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C46","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(12)60115-9","article-title":"SVR4 and SVR12 with an interferon-free regiment of BI201335 and BI207127, +\/\u2212 ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2","volume":"56","author":"Zeuzem","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C47","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","article-title":"Interferon-free treatment with a combination of mericitabine and danoprevir\/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010609_CIS391C48","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/S0168-8278(12)61426-3","article-title":"Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon\/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders","volume":"56","author":"Lok","year":"2012","journal-title":"J Hepatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/55\/suppl_1\/S16\/20910996\/cis391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T01:06:19Z","timestamp":1507943179000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/55\/suppl_1\/S16\/323640\/Recent-Successes-and-Noteworthy-Future-Prospects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,15]]},"references-count":48,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2012,7,15]]},"published-print":{"date-parts":[[2012,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cis391","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,7,15]]},"published":{"date-parts":[[2012,7,15]]}}}